Liudan Zhao
Yu Yu*- Institute for Development and Regenerative Cardiovascular Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Editorial on the Research Topic
Transcription factors in cardiovascular development and remodeling
Cardiovascular diseases (CVDs), involving diverse pathological conditions of the heart and the vascular system, are the predominant causes of death worldwide (Tsao et al., 2023). In childhood, CVDs are mainly manifested as congenital heart diseases (CHDs), which arise from abnormal or incomplete formation of cardiovascular development and affect at least 2% of newborns (Dolk et al., 2011). According to the estimation, 13.3 million people worldwide had CHDs in 2019 (Roth et al., 2020), with a high likelihood of developing physical and mental health complications across the life span. Adults are more likely to develop chronic cardiovascular disease, which includes atherosclerosis, thrombosis, myocardial infarction, hypertension, pulmonary arterial hypertension (PH), and cardiomyopathy. PH and cardiomyopathy can concomitantly appear with CHD in children. CVDs affects 48.6% of adults with ≥20 years of age (127.9 million in 2020) and increases with age in both male and female (Akinbami et al., 2022). Given that CVDs are diseases throughout the lifespan, immense health and economic burdens have been produced and it is therefore important to explore the underlying mechanisms that contribute to disease development.
Dysfunctions of cellular signaling transduction and gene expression have been widely recognized as critical molecular mechanisms in the development of CVDs (Ghigo et al., 2017). Among numerous signaling molecules, transcription factors (TFs) are essential for the development and maintenance of the cardiovascular system. The key role of a TF is to recruit transcriptional regulatory components to certain genomic loci to modulate cardiovascular genes expression and thus control important morphogenetic steps (Ptashne and Gann, 1997). Most of the inherited forms of CVDs are caused by the mutations in cardiovascular TF genes. Congenital heart defects, for example, are commonly associated with loss-of-function mutations in related TFs (Epstein and Buck, 2000). Moreover, the function of TFs in cardiovascular remodeling also has become a research hotspot, revealing novel therapeutic approaches against chronic CVDs of adults (Potente et al., 2005; Li et al., 2017; Dittrich et al., 2021). Therefore, a deeper understanding of the transcriptional regulatory mechanisms controlling cardiovascular genes crosstalks will be critical for deciphering the molecular etiology of CVDs, as well as for helping to design more powerful and specific regenerative therapies for CVDs.
The aim of this Research Topic is to shed light on recent progress and trends in the function of transcription factors in cardiovascular development and remodeling. It currently includes two research articles and two reviews from 41 authors, covering high-incidence CVDs and cutting-edge bioinformatics methods and presenting potential therapeutic genetic targets. The collection encompasses different fields of investigations as further detailed by the sections below.
Ventricular septal defect (VSD) is defined as an interruption in the interventricular septum formation during cardiac morphogenesis, accounting for 40% of all CHDs (Penny and Vick, 2011). In past 10 years, a number of gene disruptions have been shown to cause complex VSD, however functional non-coding SNPs (cis-regulatory SNPs) have not been examined systematically. Jin et al. performed an exome-wide association analysis using whole-excome sequencing data of 80 patients (includes tetralogy of fallot and pulmonary atresia with VSD) and 100 controls in Chinese children and identified 93 low-frequency noncoding SNPs associated with complex VSD risk. Specifically, rs2279658 might cause abnormal transcription of COQ2 and FAM175A in the heart, which contributes to complex VSD predisposition. These findings highlight the importance of cis-regulatory SNPs in the pathogenesis of complex VSD and broaden our knowledge of this disease.
PH is a rare but lethal disease characterized by remodeling of the pulmonary arteries, increased vascular resistance, ultimately resulted in right heart failure and even death (Walters et al., 2023). It can concomitantly appear with CHD in children and also occur in adult. Numerous studies have uncovered novel genetic risk variants involved in the pathogenesis of PH, such as hypoxia-inducible factors family. Endothelial PAS domain-containing protein 1 (EPAS1), also referred to hypoxia-inducible factor 2 alpha (HIF-2α), is mainly expressed in the endothelial cell, while its mechanism in PH still remains largely unknown. The molecular structure, biological function and regulatory network of EPAS1 in PH were presented in detail by Wang et al., which provided theoretical support for the possible novel target for future PH intervention. Additionally, the work of Yang et al. studied the role of transcription factors in various PH-related cellular mechanisms including in pulmonary arterial smooth muscle cells, pulmonary arterial endothelial cells, pulmonary arterial fibroblasts and inflammatory cells. These reviews improved the understanding of particularly interactions among transcription factors mediated cellular signaling pathways and identified novel therapies for PH.
With the increasing scale of high-throughput expression data, pathway analysis has been widely applied in the field of CVDs, which uncovered several potential mechanisms of CVDs. MicroRNAs (miRNA) is known to cause gene silencing by binding to mRNA, while competitive endogenous RNA (ceRNA) can regulate gene expression by competitively binding to miRNA. CeRNA has been shown to play the significant role in cellular biology (Song et al., 2017), in which several genes can interact with others. However, there is a lack of comprehensive analyses concerning the ceRNA-mediated pathway–pathway crosstalk in CVDs. Therefore, Song et al. utilized 21 gene expression datasets to generate a landscape of the ceRNA-mediated pathway–pathway crosstalk of eight major CVDs among adults and children. It elaborated the potential molecular regulatory mechanisms of ceRNA interaction in pathway–pathway crosstalk, which innovated the current identification methods of the pathway crosstalk.
In summary, this Research Topic gathered a broad range of high-quality articles demonstrating the latest advances of transcription factors in cardiovascular development and remodeling. More cardiovascular research beyond the four articles is needed, and future topics will address specific areas in pediatrics and adult heart research field. We welcome all articles of related research topics and hope that this Research Topic will constantly serve to inspire the scientific community and medical treatment by providing new strategy for understanding biological process and human diseases.
Author contributions
LZ wrote and revised the manuscript. YY conceived and revised the manuscript. All authors provided intellectual input to the editorial. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by the National Natural Science Foundation of China [Grant numbers 81974021, 82170304 (to YY)], and the Natural Science Foundation of Shanghai [Grant numbers 20ZR1435500 (to YY)].
Acknowledgments
We sincerely appreciate all contributing authors and reviewers for their work and dedication to this Research Topic.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Akinbami, L. J., Chen, T. C., Davy, O., Ogden, C. L., Fink, S., Clark, J., et al. (2022). National health and nutrition examination survey, 2017-march 2020 prepandemic file: Sample design, estimation, and analytic guidelines. Vital Health Stat. 1, 1–36. Available at: https://www.ncbi.nlm.nih.gov/pubmed/35593699.
Dittrich, G. M., Froese, N., Wang, X., Kroeger, H., Wang, H., Szaroszyk, M., et al. (2021). Fibroblast GATA-4 and GATA-6 promote myocardial adaptation to pressure overload by enhancing cardiac angiogenesis. Basic Res. Cardiol. 116, 26. doi:10.1007/s00395-021-00862-y
Dolk, H., Loane, M., and Garne, E.European Surveillance of Congenital Anomalies Working Group (2011). Congenital heart defects in europe: Prevalence and perinatal mortality, 2000 to 2005. Circulation 123, 841–849. doi:10.1161/CIRCULATIONAHA.110.958405
Epstein, J. A., and Buck, C. A. (2000). Transcriptional regulation of cardiac development: Implications for congenital heart disease and DiGeorge syndrome. Pediatr. Res. 48, 717–724. doi:10.1203/00006450-200012000-00003
Ghigo, A., Laffargue, M., Li, M., and Hirsch, E. (2017). PI3K and calcium signaling in cardiovascular disease. Circ. Res. 121, 282–292. doi:10.1161/CIRCRESAHA.117.310183
Li, Y., Li, Z., Zhang, C., Li, P., Wu, Y., Wang, C., et al. (2017). Cardiac fibroblast-specific activating transcription factor 3 protects against heart failure by suppressing MAP2K3-p38 signaling. Circulation 135, 2041–2057. doi:10.1161/CIRCULATIONAHA.116.024599
Penny, D. J., and Vick, G. W. (2011). Ventricular septal defect. Lancet 377, 1103–1112. doi:10.1016/S0140-6736(10)61339-6
Potente, M., Urbich, C., Sasaki, K., Hofmann, W. K., Heeschen, C., Aicher, A., et al. (2005). Involvement of Foxo transcription factors in angiogenesis and postnatal neovascularization. J. Clin. Invest. 115, 2382–2392. doi:10.1172/JCI23126
Ptashne, M., and Gann, A. (1997). Transcriptional activation by recruitment. Nature 386, 569–577. doi:10.1038/386569a0
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., et al. (2020). Global burden of cardiovascular diseases and risk factors, 1990-2019: Update from the GBD 2019 study. J. Am. Coll. Cardiol. 76, 2982–3021. doi:10.1016/j.jacc.2020.11.010
Song, C., Zhang, J., Qi, H., Feng, C., Chen, Y., Cao, Y., et al. (2017). The global view of mRNA-related ceRNA cross-talks across cardiovascular diseases. Sci. Rep. 7, 10185. doi:10.1038/s41598-017-10547-z
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., et al. (2023). Heart disease and stroke statistics-2023 update: A report from the American heart association. Circulation 147, e93–e621. doi:10.1161/CIR.0000000000001123
Keywords: transcription factors, cardiovascular disease, developmental biology, remodeling, signaling
Citation: Zhao L and Yu Y (2023) Editorial: Transcription factors in cardiovascular development and remodeling. Front. Cell Dev. Biol. 11:1225947. doi: 10.3389/fcell.2023.1225947
Received: 20 May 2023; Accepted: 01 June 2023;
Published: 06 June 2023.
Edited and reviewed by:
Ramani Ramchandran, Medical College of Wisconsin, United StatesCopyright © 2023 Zhao and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yu Yu, eXV5dUB4aW5odWFtZWQuY29tLmNu